Biocept, Inc.

NasdaqCM:BIOC Rapporto sulle azioni

Cap. di mercato: US$2.7m

Biocept Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Biocept has a total shareholder equity of $290.0K and total debt of $526.0K, which brings its debt-to-equity ratio to 181.4%. Its total assets and total liabilities are $22.1M and $21.8M respectively.

Informazioni chiave

181.4%

Rapporto debito/patrimonio netto

US$526.00k

Debito

Indice di copertura degli interessin/a
ContantiUS$6.63m
Patrimonio nettoUS$290.00k
Totale passivitàUS$21.81m
Totale attivitàUS$22.10m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19
Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03
Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13
Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Jan 26
We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Dec 22
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Nov 20

Biocept +4% on COVID-19 testing update

Nov 12

Analisi della posizione finanziaria

Passività a breve termine: BIOC's short term assets ($8.9M) exceed its short term liabilities ($4.9M).

Passività a lungo termine: BIOC's short term assets ($8.9M) do not cover its long term liabilities ($16.9M).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: BIOC has more cash than its total debt.

Riduzione del debito: BIOC's debt to equity ratio has increased from 20% to 181.4% over the past 5 years.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: BIOC has less than a year of cash runway based on its current free cash flow.

Previsione Cash Runway: BIOC has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.3% each year.


Scoprire le aziende sane